Target intelligence / Profile preview

T cell receptor beta joining 2-4 (TRBJ2-4)

Target
TRBJ2-4
Molecular classification
T cell receptor subunit, Receptor component, Immunoglobulin superfamily (IgSF) domain
01

Overview

T cell receptor beta joining 2-4 (TRBJ2-4) is a gene segment that encodes the joining (J) region of the variable domain of the T cell receptor (TCR) beta chain[1][7]. The TCR beta chain is a crucial component of the αβ T cell receptor complex, which is essential for the adaptive immune response. The TRBJ2-4 segment, along with variable (V) and diversity (D) gene segments, is somatically recombined during T cell development in the thymus to generate the complementarity-determining region 3 (CDR3) of the TCR, the primary site for antigen recognition[1][3][4][5]. The resulting αβ TCR is present on T lymphocytes and is responsible for recognizing peptide-major histocompatibility (MH) complexes on antigen presenting cells, triggering T cell activation and downstream signaling pathways necessary for T cell function, growth, and differentiation[1][2][5]. TRBJ2-4 itself is not a druggable target, but rather one of many gene segments contributing to TCR diversity and function[1][5][7].

Other names
TRBJ2-4TRBJ24TCRBJ2S4TCRBJ2S4 (redundant)TRBJ24 (redundant)
02

Biological functions

Adaptive immune responseAntigen recognitionSignal transduction
03

Disease associations

Other (T cell development, antigen repertoire in immunity; alterations may theoretically be relevant in lymphoid malignancies or immune disorders but there is no evidence of specific drug targeting or direct disease association[1][5])

Beyond the preview

Go deeper on T cell receptor beta joining 2-4 (TRBJ2-4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T cell receptor beta joining 2-4 (TRBJ2-4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call